<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14291">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316693</url>
  </required_header>
  <id_info>
    <org_study_id>104798</org_study_id>
    <nct_id>NCT00316693</nct_id>
  </id_info>
  <brief_title>Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity &amp; Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine</brief_title>
  <official_title>A Phase II Study to Assess the Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 (Cervarix TM) Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Japanese Female Subjects Aged 20 - 25 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Japan: Pharmaceutical and Medical Device Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infection with human papillomavirus (HPV) has been clearly established as the central cause
      of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of
      the uterus or womb). This infection may go away by itself, but if it does not go away (this
      is called persistent infection), it can lead in women over a long period of time to cancer
      of the cervix. This study will evaluate the efficacy in prevention of persistent HPV-16 or
      HPV-18 cervical infection lasting at least 6 months, the immunogenicity and safety of GSK
      Biologicals HPV-16/18 vaccine (Cervarix TM ) over 24 months in Japanese adult women aged 20
      - 25 years of age at study start. Approximately 1000 study subjects will either receive the
      HPV vaccine or a control vaccine (Hepatitis A vaccine) administered intramuscularly
      according to a 0-1-6 month schedule.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Protocol Posting has been updated to reflect changes as a consequence of an amendment to
      the protocol. Sections impacted are Official Title of the study and Intervention name.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Subjects With Persistent Cervical Infection With Human Papillomavirus 16 (HPV-16) or Human Papillomavirus 18 (HPV-18)</measure>
    <time_frame>Throughout the study period (up to Month 24)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Persistent HPV-16 or HPV-18 infection is defined as at least 2 positive Human Papillomavirus (HPV) deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) assays for the same viral genotype with no negative DNA sample between the 2 positive DNA samples, over an approximate interval of 6 months (&gt; 150 days) [as assessed in women who were, for the corresponding HPV type, seronegative at Month 0 and HPV DNA negative (by PCR) at Month 0 and Month 6].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Incident Cervical Infection With Human Papillomavirus 16 (HPV-16) or Human Papillomavirus 18 (HPV-18)</measure>
    <time_frame>Up to Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>HPV-16 or HPV-18 incident infection is defined as at least one positive HPV-16 or HPV-18 deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) assay in women who were, for the corresponding HPV type, seronegative at Month 0 and HPV DNA negative (by PCR) at Month 0 and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Cytologically-confirmed Abnormalities Concurrently Associated With Human Papillomavirus 16 (HPV-16) and/or Human Papillomavirus 18 (HPV-18) Cervical Infection</measure>
    <time_frame>Up to Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cytologically-confirmed abnormalities assessed include atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), atypical squamous cells-can not exclude HSIL (ASC-H) and atypical glandular cells (AGC). These cytological abnormalities were assessed in women who were, for the corresponding Human Papillomavirus (HPV) type, seronegative at Month 0 and HPV deoxyribonucleic acid (DNA) negative (by polymerase chain reaction) at Month 0 and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically-confirmed Lesions Concurrently Associated With Human Papillomavirus 16 (HPV-16) and/or Human Papillomavirus (HPV-18) Cervical Infection</measure>
    <time_frame>Up to Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Histopathologically-confirmed lesions assessed include cervical intraepithelial neoplasia of grade 1 (CIN1), grade 2 (CIN2), grade 3 (CIN3) and adenocarcinoma. These lesions were assessed in women who were, for the corresponding Human Papillomavirus (HPV) type, seronegative at Month 0 and HPV deoxyribonucleic acid (DNA) negative (by polymerase chain reaction) at Month 0 and Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Incident Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Types</measure>
    <time_frame>Up to Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incident infection for oncogenic HPV types is defined as at least one positive oncogenic HPV type deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) assay in women who were, for the corresponding HPV type, HPV DNA negative (by PCR) at Month 0 and Month 6.
Oncogenic (high risk [HR]) HPV types assessed include HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Types</measure>
    <time_frame>Up to Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Persistent infection for oncogenic HPV types is defined as at least 2 positive HPV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) assays for the same viral genotype with no negative DNA sample between the 2 positive DNA samples, over an approximate interval of 6 months (&gt; 150 days) [as assessed in women who were, for the corresponding HPV type, HPV DNA negative (by PCR) at Month 0 and Month 6].
Oncogenic (high risk [HR]) HPV types assessed include HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Cytologically-confirmed Abnormalities Concurrently Associated With Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Type</measure>
    <time_frame>Up to Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cytologically-confirmed abnormalities assessed include ASC-US, LSIL, HSIL, ASC-H and AGC. These cytological abnormalities were assessed in women who were, for the corresponding HPV type (determined by PCR), HPV DNA negative (by PCR) at Month 0 and Month 6.
Oncogenic (high risk [HR]) HPV types assessed include HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically Confirmed Lesions Concurrently Associated With Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Type</measure>
    <time_frame>Up to Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Histopathologically-confirmed lesions assessed include cervical intraepithelial neoplasia of grade 1 (CIN1), grade 2 (CIN2), grade 3 (CIN3) and adenocarcinoma. These lesions were assessed in women who were, for the corresponding HPV type (determined by polymerase chain reaction)), HPV deoxyribonucleic acid (DNA) negative at Month 0 and Month 6.
Oncogenic (high risk [HR]) HPV types assessed include HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-human Papillomavirus 16 and 18 (Anti-HPV-16 and Anti-HPV-18) Antibody Titers Above the Cut-off Value</measure>
    <time_frame>At Months 0 (pre-vaccination), 6, 7, 12, 18 and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-HPV-16 antibody cut-off value assessed include 8 ELISA units per milliliter (EL.U/mL) and anti-HPV-18 antibody cut-off value assessed include 7 EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</measure>
    <time_frame>At Months 0, 6, 7, 12, 18 and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and General Symptoms</measure>
    <time_frame>Within 7 days after each and any vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include arthralgia, fatigue, fever (above 37.5 degree Celsius), gastrointestinal symptoms, headache, myalgia, rash and urticaria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AE)</measure>
    <time_frame>Within 30 days after any vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAE)</measure>
    <time_frame>Throughout the study period (up to Month 24)</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Other Medically Significant Conditions (MSCs)</measure>
    <time_frame>Throughout the study period (up to Month 24)</time_frame>
    <safety_issue>No</safety_issue>
    <description>NOCDs include autoimmune disorders, asthma, type I diabetes, allergies. MSC include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of Any Reported Pregnancies</measure>
    <time_frame>Throughout the study period (up to Month 24)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Information on any subject who became pregnant while participating in this study was collected. The outcomes of the pregnancies are reported below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinically Relevant Abnormalities in Hematological Parameters</measure>
    <time_frame>At Month 0 and Month 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hematological parameters assessed in blood samples include hemoglobin, haematocrit, mean corpuscular (MC) hemoglobin, mean corpuscular (MC) hemoglobin concentration, mean corpuscular (MC) volume, platelet count, red blood cell count, white blood cell count.
Abnormalities reported include values outside the normal ranges: values higher than normal are designated as &quot;Above&quot; and values lower than normal as &quot;Below&quot; while &quot;Unknown&quot; stands for values not determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical Parameters</measure>
    <time_frame>At Month 0 and Month 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biochemical parameters were assessed in blood samples. Abnormalities reported include values outside the normal ranges: values higher than normal are designated as &quot;Above&quot; and values lower than normal as &quot;Below&quot; while &quot;Unknown&quot; stands for values not determined.
Abbreviations: aminotransferase (ALT), aspartate aminotransferase (ASP), C reactive protein (CRP), gamma-glutamyl-transferase (GGT) and lactate dehydrogenase (LDH).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Abnormal Biochemical Parameters in Urine Samples</measure>
    <time_frame>At Month 0 and Month 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Abnormalities in concentrations (expressed as milligrams per deciliter [mg/dL]) are presented categorical as follows:
Protein: &lt;10 (-)*; 10-25 (+-)*; 25-85 (+); 85-250 (2+); 250-800 (3+).
Glucose: &lt;30 (-)*; 30-60 (+-)*; 60-125 (+); 125-250 (2+); 250-750 (3+).
Urobilinogen: &lt;1.5 (+-)*; 1.5-3.5 (+); 3.5-7 (2+); 7-14 (3+).
Bilirubin: &lt;0.35 (-)*; 0.35-1.5 (+); 1.5-5 (2+); 5-12 (3+).
Occult blood: &lt;0.015 (-)*; 0.015-0.045 (+-); 0.045-015 (+); 0.15-0.75 (2+); &gt;0.75 (3+).
Ketone body: &lt;2.5 (-)*; 2.5-7.5 (+-); 7.5-30 (+); 30-70 (2+); 70-125 (3+).
Normal ranges indicated by asterix*.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1046</enrollment>
  <condition>Human Papillomavirus (HPV) Infection</condition>
  <condition>Papillomavirus Vaccines</condition>
  <condition>Cervical Neoplasia</condition>
  <arm_group>
    <arm_group_label>Cervarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aimmugen Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPV-16/18 vaccine (Cervarix™)</intervention_name>
    <description>Intramuscular injection, 3 doses</description>
    <arm_group_label>Cervarix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aimmugen™</intervention_name>
    <description>Intramuscular injection, 3 doses</description>
    <arm_group_label>Aimmugen Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Subjects who the investigator/co-investigator believes that they can and will comply
             with the requirements of the protocol should be enrolled in the study.

          -  A Japanese female subject between, and including, 20 and 25 years of age at the time
             of the first vaccination.

          -  Written informed consent obtained from the subject prior to enrolment.

          -  Healthy subjects as established by medical history and history-oriented clinical
             examination before entering into the study.

          -  Subjects must have a negative urine pregnancy test.

          -  Subjects must be of non-childbearing potential, she must be abstinent or have used
             adequate contraceptive precautions for 30 days prior to vaccination, have a negative
             pregnancy test and must agree to continue such precautions for two months after
             completion of the vaccination series.

          -  Subject must have an intact cervix

        Exclusion criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine/control within 30 days preceding the first dose of study
             vaccine/control, or planned use during the study period.

          -  Pregnant or breastfeeding women. Women must be at least 3 months post-pregnancy and
             not breastfeeding to enter the study.

          -  A women planning to become pregnant, likely to become pregnant or planning to
             discontinue contraceptive precautions during the study period, up to 2 months after
             the last vaccine dose

          -  previous administration of components of the investigational vaccine

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  Planned administration/ administration of a vaccine not foreseen by the study
             protocol within 30 days before and 30 days after the first dose of vaccine. Routine
             vaccines may be allowed up to 8 days before the first dose of study vaccine.

          -  Previous vaccination against HPV.

          -  History of vaccination against hepatitis A or a known clinical history of hepatitis A
             disease

          -  Administration of immunoglobulin and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the study vaccines

          -  Hypersensitivity to latex

          -  Known acute or chronic, clinically significant pulmonary, cardiovascular, neurologic,
             hepatic or renal functional abnormality, as determined by previous physical
             examination or laboratory tests.

          -  Cancer or autoimmune disease under treatment.

          -  History of having had colposcopy or has planned a colposcopy to evaluate an abnormal
             cervical cytology (Pap smear) test.

          -  Heavy bleeding or heavy vaginal discharge such that a pelvic examination can not be
             performed

          -  Acute disease at the time of enrolment.

          -  Oral temperature &gt;= 37.5°C / axillary temperature &gt; 37.5°C.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <reference>
    <citation>Konno R et al. Efficacy, immunogenicity and safety of HPV 16/18 AS04-adjuvanted vaccine in Japanese women. Abstract presented at European Research Organization on Genital Infection and Neoplasia 2010 (EUROGIN). Monte Carlo, Monaco, 17-20 February 2010.</citation>
  </reference>
  <reference>
    <citation>Konno R et al. Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study. Abstract presented at European Research Organization on Genital Infection and Neoplasia 2011 (EUROGIN). Lisbon, Portugal, 8-11 May 2011.</citation>
  </reference>
  <reference>
    <citation>Konno R, Dobbelaere KO, Godeaux OO, Tamura S, Yoshikawa H. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7. Int J Gynecol Cancer. 2009 Jul;19(5):905-11. doi: 10.1111/IGC.0b013e3181a23c0e.</citation>
    <PMID>19574783</PMID>
  </reference>
  <reference>
    <citation>Konno R et al. Interim analysis of clinical trial of HPV-16/18-AS04 vaccine in Japan. Abstract presented at the 25th International Papillomavirus Conference, Malmö, Sweden, 8-14 May 2009.</citation>
  </reference>
  <reference>
    <citation>Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 2008 Dec 2;26(51):6630-8. doi: 10.1016/j.vaccine.2008.09.049.</citation>
    <PMID>18845199</PMID>
  </reference>
  <reference>
    <citation>Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial. Int J Gynecol Cancer. 2010 Apr;20(3):404-10. doi: 10.1111/IGC.0b013e3181d373a5.</citation>
    <PMID>20375805</PMID>
  </reference>
  <reference>
    <citation>Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study. Cancer Sci. 2011 Apr;102(4):877-82. doi: 10.1111/j.1349-7006.2011.01878.x. Epub 2011 Feb 17.</citation>
    <PMID>21251162</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>April 11, 2013</lastchanged_date>
  <firstreceived_date>April 19, 2006</firstreceived_date>
  <firstreceived_results_date>November 12, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV Vaccine Efficacy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Six subjects enrolled in this study were not vaccinated and hence not reported as started in the participant flow table below.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
        </group>
        <group group_id="P2">
          <title>Aimmugen Group</title>
          <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="519"/>
                <participants group_id="P2" count="521"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="442"/>
                <participants group_id="P2" count="436"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
        </group>
        <group group_id="B2">
          <title>Aimmugen Group</title>
          <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="519"/>
                <measurement group_id="B2" value="521"/>
                <measurement group_id="B3" value="1040"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="22.4" spread="1.7"/>
                <measurement group_id="B2" value="22.5" spread="1.6"/>
                <measurement group_id="B3" value="22.5" spread="1.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="519"/>
                <measurement group_id="B2" value="521"/>
                <measurement group_id="B3" value="1040"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Persistent Cervical Infection With Human Papillomavirus 16 (HPV-16) or Human Papillomavirus 18 (HPV-18)</title>
        <description>Persistent HPV-16 or HPV-18 infection is defined as at least 2 positive Human Papillomavirus (HPV) deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) assays for the same viral genotype with no negative DNA sample between the 2 positive DNA samples, over an approximate interval of 6 months (&gt; 150 days) [as assessed in women who were, for the corresponding HPV type, seronegative at Month 0 and HPV DNA negative (by PCR) at Month 0 and Month 6].</description>
        <time_frame>Throughout the study period (up to Month 24)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="387"/>
                  <measurement group_id="O2" value="392"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Persistent Cervical Infection With Human Papillomavirus 16 (HPV-16) or Human Papillomavirus 18 (HPV-18)</title>
            <description>Persistent HPV-16 or HPV-18 infection is defined as at least 2 positive Human Papillomavirus (HPV) deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) assays for the same viral genotype with no negative DNA sample between the 2 positive DNA samples, over an approximate interval of 6 months (&gt; 150 days) [as assessed in women who were, for the corresponding HPV type, seronegative at Month 0 and HPV DNA negative (by PCR) at Month 0 and Month 6].</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>HPV-16/18 (n=387,392)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-16 (n=332,340)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 (n=346,343)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Incident Cervical Infection With Human Papillomavirus 16 (HPV-16) or Human Papillomavirus 18 (HPV-18)</title>
        <description>HPV-16 or HPV-18 incident infection is defined as at least one positive HPV-16 or HPV-18 deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) assay in women who were, for the corresponding HPV type, seronegative at Month 0 and HPV DNA negative (by PCR) at Month 0 and Month 6.</description>
        <time_frame>Up to Month 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="408"/>
                  <measurement group_id="O2" value="406"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Incident Cervical Infection With Human Papillomavirus 16 (HPV-16) or Human Papillomavirus 18 (HPV-18)</title>
            <description>HPV-16 or HPV-18 incident infection is defined as at least one positive HPV-16 or HPV-18 deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) assay in women who were, for the corresponding HPV type, seronegative at Month 0 and HPV DNA negative (by PCR) at Month 0 and Month 6.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>HPV-16/18 (n=408,406)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-16 (n=351,353)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 (n=359,355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Cytologically-confirmed Abnormalities Concurrently Associated With Human Papillomavirus 16 (HPV-16) and/or Human Papillomavirus 18 (HPV-18) Cervical Infection</title>
        <description>Cytologically-confirmed abnormalities assessed include atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), atypical squamous cells-can not exclude HSIL (ASC-H) and atypical glandular cells (AGC). These cytological abnormalities were assessed in women who were, for the corresponding Human Papillomavirus (HPV) type, seronegative at Month 0 and HPV deoxyribonucleic acid (DNA) negative (by polymerase chain reaction) at Month 0 and Month 6.</description>
        <time_frame>Up to Month 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="408"/>
                  <measurement group_id="O2" value="406"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Cytologically-confirmed Abnormalities Concurrently Associated With Human Papillomavirus 16 (HPV-16) and/or Human Papillomavirus 18 (HPV-18) Cervical Infection</title>
            <description>Cytologically-confirmed abnormalities assessed include atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), atypical squamous cells-can not exclude HSIL (ASC-H) and atypical glandular cells (AGC). These cytological abnormalities were assessed in women who were, for the corresponding Human Papillomavirus (HPV) type, seronegative at Month 0 and HPV deoxyribonucleic acid (DNA) negative (by polymerase chain reaction) at Month 0 and Month 6.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>HPV-16/18 (n=408,406)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-16 (n=351,353)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 (n=359,355)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically-confirmed Lesions Concurrently Associated With Human Papillomavirus 16 (HPV-16) and/or Human Papillomavirus (HPV-18) Cervical Infection</title>
        <description>Histopathologically-confirmed lesions assessed include cervical intraepithelial neoplasia of grade 1 (CIN1), grade 2 (CIN2), grade 3 (CIN3) and adenocarcinoma. These lesions were assessed in women who were, for the corresponding Human Papillomavirus (HPV) type, seronegative at Month 0 and HPV deoxyribonucleic acid (DNA) negative (by polymerase chain reaction) at Month 0 and Month 6.</description>
        <time_frame>Up to Month 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="408"/>
                  <measurement group_id="O2" value="407"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Histopathologically-confirmed Lesions Concurrently Associated With Human Papillomavirus 16 (HPV-16) and/or Human Papillomavirus (HPV-18) Cervical Infection</title>
            <description>Histopathologically-confirmed lesions assessed include cervical intraepithelial neoplasia of grade 1 (CIN1), grade 2 (CIN2), grade 3 (CIN3) and adenocarcinoma. These lesions were assessed in women who were, for the corresponding Human Papillomavirus (HPV) type, seronegative at Month 0 and HPV deoxyribonucleic acid (DNA) negative (by polymerase chain reaction) at Month 0 and Month 6.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>HPV-16/18 (n=408,407)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-16 (n=351,353)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 (n=359,356)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Incident Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Types</title>
        <description>Incident infection for oncogenic HPV types is defined as at least one positive oncogenic HPV type deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) assay in women who were, for the corresponding HPV type, HPV DNA negative (by PCR) at Month 0 and Month 6.
Oncogenic (high risk [HR]) HPV types assessed include HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68.</description>
        <time_frame>Up to Month 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="446"/>
                  <measurement group_id="O2" value="436"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Incident Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Types</title>
            <description>Incident infection for oncogenic HPV types is defined as at least one positive oncogenic HPV type deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) assay in women who were, for the corresponding HPV type, HPV DNA negative (by PCR) at Month 0 and Month 6.
Oncogenic (high risk [HR]) HPV types assessed include HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>HPV-16 (n=119,398)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 (n=428,407)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-31 (n=428,416)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-33 (n=444,435)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-35 (n=443,432)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-39 (n=422,418)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-45 (n=446,433)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-51 (n=413,412)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-52 (n=404,383)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-56 (n=423,414)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-58 (n=432,411)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-59 (n=443,427)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-66 (n=426,410)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-68 (n=436,424)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any HR HPV types except HPV-16/18 (n=446,436)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                  <measurement group_id="O2" value="113"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any HR HPV types (n=446,436)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                  <measurement group_id="O2" value="134"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Types</title>
        <description>Persistent infection for oncogenic HPV types is defined as at least 2 positive HPV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) assays for the same viral genotype with no negative DNA sample between the 2 positive DNA samples, over an approximate interval of 6 months (&gt; 150 days) [as assessed in women who were, for the corresponding HPV type, HPV DNA negative (by PCR) at Month 0 and Month 6].
Oncogenic (high risk [HR]) HPV types assessed include HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68.</description>
        <time_frame>Up to Month 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="424"/>
                  <measurement group_id="O2" value="422"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Persistent Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Types</title>
            <description>Persistent infection for oncogenic HPV types is defined as at least 2 positive HPV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) assays for the same viral genotype with no negative DNA sample between the 2 positive DNA samples, over an approximate interval of 6 months (&gt; 150 days) [as assessed in women who were, for the corresponding HPV type, HPV DNA negative (by PCR) at Month 0 and Month 6].
Oncogenic (high risk [HR]) HPV types assessed include HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>HPV-16 (n=398,384)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 (n=408,394)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-31 (n=406,403)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-33 (n=422,421)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-35 (n=422,418)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-39 (n=401,406)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-45 (n=424,419)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-51 (n=395,398)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-52 (n=383,371)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-56 (n=403,400)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-58 (n=410,399)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-59 (n=422,413)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-66 (n=404,396)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-68 (n=415,410)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any HR HPV types except HPV-16/18 (n=424,422)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any HR HPV types (n=424,422)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="53"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Cytologically-confirmed Abnormalities Concurrently Associated With Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Type</title>
        <description>Cytologically-confirmed abnormalities assessed include ASC-US, LSIL, HSIL, ASC-H and AGC. These cytological abnormalities were assessed in women who were, for the corresponding HPV type (determined by PCR), HPV DNA negative (by PCR) at Month 0 and Month 6.
Oncogenic (high risk [HR]) HPV types assessed include HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68.</description>
        <time_frame>Up to Month 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="446"/>
                  <measurement group_id="O2" value="436"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Cytologically-confirmed Abnormalities Concurrently Associated With Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Type</title>
            <description>Cytologically-confirmed abnormalities assessed include ASC-US, LSIL, HSIL, ASC-H and AGC. These cytological abnormalities were assessed in women who were, for the corresponding HPV type (determined by PCR), HPV DNA negative (by PCR) at Month 0 and Month 6.
Oncogenic (high risk [HR]) HPV types assessed include HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>HPV-16 (n=419,398)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 (n=428,407)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-31 (n=428,416)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-33 (n=444,435)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-35 (n=443,432)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-39 (n=422,418)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-45 (n=446,433)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-51 (n=413,412)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-52 (n=404,383)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-56 (n=423,414)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-58 (n=432,411)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-59 (n=443,427)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-66 (n=426,410)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-68 (n=436,424)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any HR HPV types except HPV-16/18 (n=446,436)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any HR HPV types (n=446,436)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically Confirmed Lesions Concurrently Associated With Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Type</title>
        <description>Histopathologically-confirmed lesions assessed include cervical intraepithelial neoplasia of grade 1 (CIN1), grade 2 (CIN2), grade 3 (CIN3) and adenocarcinoma. These lesions were assessed in women who were, for the corresponding HPV type (determined by polymerase chain reaction)), HPV deoxyribonucleic acid (DNA) negative at Month 0 and Month 6.
Oncogenic (high risk [HR]) HPV types assessed include HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68.</description>
        <time_frame>Up to Month 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="446"/>
                  <measurement group_id="O2" value="438"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Histopathologically Confirmed Lesions Concurrently Associated With Cervical Infection With Any Oncogenic Human Papillomavirus (HPV) Type</title>
            <description>Histopathologically-confirmed lesions assessed include cervical intraepithelial neoplasia of grade 1 (CIN1), grade 2 (CIN2), grade 3 (CIN3) and adenocarcinoma. These lesions were assessed in women who were, for the corresponding HPV type (determined by polymerase chain reaction)), HPV deoxyribonucleic acid (DNA) negative at Month 0 and Month 6.
Oncogenic (high risk [HR]) HPV types assessed include HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>HPV-16 (n=419,400)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 (n=428,409)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-31 (n=428,417)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-33 (n=444,437)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-35 (n=443,434)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-39 (n=422,419)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-45 (n=446,435)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-51 (n=413,413)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-52 (n=404,385)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-56 (n=423,415)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-58 (n=432,413)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-59 (n=443,429)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-66 (n=426,412)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-68 (n=436,425)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any HR HPV types except HPV-16/18 (n=446,438)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any HR HPV types (n=446,438)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-human Papillomavirus 16 and 18 (Anti-HPV-16 and Anti-HPV-18) Antibody Titers Above the Cut-off Value</title>
        <description>Anti-HPV-16 antibody cut-off value assessed include 8 ELISA units per milliliter (EL.U/mL) and anti-HPV-18 antibody cut-off value assessed include 7 EL.U/mL.</description>
        <time_frame>At Months 0 (pre-vaccination), 6, 7, 12, 18 and 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="411"/>
                  <measurement group_id="O2" value="393"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Anti-human Papillomavirus 16 and 18 (Anti-HPV-16 and Anti-HPV-18) Antibody Titers Above the Cut-off Value</title>
            <description>Anti-HPV-16 antibody cut-off value assessed include 8 ELISA units per milliliter (EL.U/mL) and anti-HPV-18 antibody cut-off value assessed include 7 EL.U/mL.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>HPV-16 (pre-vaccination) [n=411,393]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-16 (Month 6) [n=411,393]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="411"/>
                  <measurement group_id="O2" value="55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-16 (Month 7) [n=410,387]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="410"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-16 (Month 12) [n=373,334]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="373"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-16 (Month 18) [n=356,307]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="356"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-16 (Month 24) [n=351,295]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="351"/>
                  <measurement group_id="O2" value="38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 (pre-vaccination) [n=410,390]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 (Month 6) [n=410,388]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="410"/>
                  <measurement group_id="O2" value="53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 (Month 7) [n=409,385]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="409"/>
                  <measurement group_id="O2" value="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 (Month 12) [n=372,329]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="372"/>
                  <measurement group_id="O2" value="55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 (Month 18) [n=355,302]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="355"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 (Month 24) [n=350,288]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="350"/>
                  <measurement group_id="O2" value="38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
        <time_frame>At Months 0, 6, 7, 12, 18 and 24</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="411"/>
                  <measurement group_id="O2" value="393"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</title>
            <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 (Month 0) [n=411,393]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.5" lower_limit="5.1" upper_limit="5.9"/>
                  <measurement group_id="O2" value="5.3" lower_limit="4.9" upper_limit="5.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 (Month 6) [n=411,393]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="708.4" lower_limit="650.1" upper_limit="772.0"/>
                  <measurement group_id="O2" value="5.4" lower_limit="4.9" upper_limit="5.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 (Month 7) [n=410,387]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7441.0" lower_limit="6854.3" upper_limit="8077.8"/>
                  <measurement group_id="O2" value="5.3" lower_limit="4.9" upper_limit="5.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 (Month 12) [n=373,334]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2877.7" lower_limit="2623.1" upper_limit="3156.9"/>
                  <measurement group_id="O2" value="5.3" lower_limit="4.9" upper_limit="5.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 (Month 18) [n=356,307]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1864.8" lower_limit="1694.5" upper_limit="2052.2"/>
                  <measurement group_id="O2" value="5.3" lower_limit="4.8" upper_limit="5.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 (Month 24) [n=351,295]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1532.2" lower_limit="1395.1" upper_limit="1682.7"/>
                  <measurement group_id="O2" value="5.4" lower_limit="4.9" upper_limit="5.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 (Month 0) [n=410,390]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.5" lower_limit="4.2" upper_limit="4.8"/>
                  <measurement group_id="O2" value="4.4" lower_limit="4.1" upper_limit="4.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 (Month 6) [n=410,388]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="504.6" lower_limit="464.6" upper_limit="548.1"/>
                  <measurement group_id="O2" value="4.4" lower_limit="4.1" upper_limit="4.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 (Month 7) [n=409,385]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3805.4" lower_limit="3515.6" upper_limit="4119.1"/>
                  <measurement group_id="O2" value="4.5" lower_limit="4.2" upper_limit="4.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 (Month 12) [n=372,329]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1330.7" lower_limit="1210.2" upper_limit="1463.2"/>
                  <measurement group_id="O2" value="4.5" lower_limit="4.2" upper_limit="4.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 (Month 18) [n=355,302]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="782.0" lower_limit="703.4" upper_limit="869.5"/>
                  <measurement group_id="O2" value="4.4" lower_limit="4.1" upper_limit="4.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 (Month 24) [n=350,288]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="627.8" lower_limit="566.3" upper_limit="696.0"/>
                  <measurement group_id="O2" value="4.4" lower_limit="4.1" upper_limit="4.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and General Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include arthralgia, fatigue, fever (above 37.5 degree Celsius), gastrointestinal symptoms, headache, myalgia, rash and urticaria.</description>
        <time_frame>Within 7 days after each and any vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="512"/>
                  <measurement group_id="O2" value="511"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited Local and General Symptoms</title>
            <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include arthralgia, fatigue, fever (above 37.5 degree Celsius), gastrointestinal symptoms, headache, myalgia, rash and urticaria.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pain (n=512,510)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="508"/>
                  <measurement group_id="O2" value="214"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness (n=512,510)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="455"/>
                  <measurement group_id="O2" value="287"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling (n=512,510)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="401"/>
                  <measurement group_id="O2" value="165"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia (n=512,511)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="123"/>
                  <measurement group_id="O2" value="61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue (n=512,511)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="341"/>
                  <measurement group_id="O2" value="300"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (n=512,511)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastro-intestinal symptoms (n=512,511)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="172"/>
                  <measurement group_id="O2" value="167"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache (n=512,511)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="250"/>
                  <measurement group_id="O2" value="222"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia (n=512,511)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="262"/>
                  <measurement group_id="O2" value="128"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash (n=512,511)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urticaria (n=512,511)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>Within 30 days after any vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="519"/>
                  <measurement group_id="O2" value="521"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
            <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="294"/>
                  <measurement group_id="O2" value="266"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Throughout the study period (up to Month 24)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="519"/>
                  <measurement group_id="O2" value="521"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Other Medically Significant Conditions (MSCs)</title>
        <description>NOCDs include autoimmune disorders, asthma, type I diabetes, allergies. MSC include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
        <time_frame>Throughout the study period (up to Month 24)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="519"/>
                  <measurement group_id="O2" value="521"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Other Medically Significant Conditions (MSCs)</title>
            <description>NOCDs include autoimmune disorders, asthma, type I diabetes, allergies. MSC include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>NOCDs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MSCs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="91"/>
                  <measurement group_id="O2" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome of Any Reported Pregnancies</title>
        <description>Information on any subject who became pregnant while participating in this study was collected. The outcomes of the pregnancies are reported below.</description>
        <time_frame>Throughout the study period (up to Month 24)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on those subjects reporting pregnancy during the study period.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Outcome of Any Reported Pregnancies</title>
            <description>Information on any subject who became pregnant while participating in this study was collected. The outcomes of the pregnancies are reported below.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Normal infant</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Premature birth</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Elective termination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Spontaneous abortion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lost to follow-up</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pregnancy ongoing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Hematological Parameters</title>
        <description>Hematological parameters assessed in blood samples include hemoglobin, haematocrit, mean corpuscular (MC) hemoglobin, mean corpuscular (MC) hemoglobin concentration, mean corpuscular (MC) volume, platelet count, red blood cell count, white blood cell count.
Abnormalities reported include values outside the normal ranges: values higher than normal are designated as &quot;Above&quot; and values lower than normal as &quot;Below&quot; while &quot;Unknown&quot; stands for values not determined.</description>
        <time_frame>At Month 0 and Month 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="519"/>
                  <measurement group_id="O2" value="521"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Hematological Parameters</title>
            <description>Hematological parameters assessed in blood samples include hemoglobin, haematocrit, mean corpuscular (MC) hemoglobin, mean corpuscular (MC) hemoglobin concentration, mean corpuscular (MC) volume, platelet count, red blood cell count, white blood cell count.
Abnormalities reported include values outside the normal ranges: values higher than normal are designated as &quot;Above&quot; and values lower than normal as &quot;Below&quot; while &quot;Unknown&quot; stands for values not determined.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Hemoglobin Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="499"/>
                  <measurement group_id="O2" value="498"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="448"/>
                  <measurement group_id="O2" value="444"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="501"/>
                  <measurement group_id="O2" value="506"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="448"/>
                  <measurement group_id="O2" value="456"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet count Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="504"/>
                  <measurement group_id="O2" value="514"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet count Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet count Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet count Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet count Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="456"/>
                  <measurement group_id="O2" value="461"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet count Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet count Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet count Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red Blood Cells count Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="514"/>
                  <measurement group_id="O2" value="515"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red Blood Cells count Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red Blood Cells count Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red Blood Cells count Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red Blood Cells count Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="457"/>
                  <measurement group_id="O2" value="463"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red Blood Cells count Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red Blood Cells count Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red Blood Cells count Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cells count Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="496"/>
                  <measurement group_id="O2" value="499"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cells count Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cells count Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cells count Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cells count Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="440"/>
                  <measurement group_id="O2" value="453"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cells count Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cells count Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cells count Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="489"/>
                  <measurement group_id="O2" value="491"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="441"/>
                  <measurement group_id="O2" value="439"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin concentration Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="495"/>
                  <measurement group_id="O2" value="488"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin concentration Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin concentration Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin concentration Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin concentration Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="442"/>
                  <measurement group_id="O2" value="434"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin concentration Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin concentration Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC hemoglobin concentration Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC volume Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="504"/>
                  <measurement group_id="O2" value="505"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC volume Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC volume Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC volume Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC volume Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="457"/>
                  <measurement group_id="O2" value="456"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC volume Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC volume Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MC volume Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical Parameters</title>
        <description>Biochemical parameters were assessed in blood samples. Abnormalities reported include values outside the normal ranges: values higher than normal are designated as &quot;Above&quot; and values lower than normal as &quot;Below&quot; while &quot;Unknown&quot; stands for values not determined.
Abbreviations: aminotransferase (ALT), aspartate aminotransferase (ASP), C reactive protein (CRP), gamma-glutamyl-transferase (GGT) and lactate dehydrogenase (LDH).</description>
        <time_frame>At Month 0 and Month 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="519"/>
                  <measurement group_id="O2" value="521"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical Parameters</title>
            <description>Biochemical parameters were assessed in blood samples. Abnormalities reported include values outside the normal ranges: values higher than normal are designated as &quot;Above&quot; and values lower than normal as &quot;Below&quot; while &quot;Unknown&quot; stands for values not determined.
Abbreviations: aminotransferase (ALT), aspartate aminotransferase (ASP), C reactive protein (CRP), gamma-glutamyl-transferase (GGT) and lactate dehydrogenase (LDH).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Albumin Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="519"/>
                  <measurement group_id="O2" value="521"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="466"/>
                  <measurement group_id="O2" value="472"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin/Globulin ratio Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="483"/>
                  <measurement group_id="O2" value="488"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin/Globulin ratio Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin/Globulin ratio Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin/Globulin ratio Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin/Globulin ratio Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="421"/>
                  <measurement group_id="O2" value="443"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin/Globulin ratio Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin/Globulin ratio Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin/Globulin ratio Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline phosphatase Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="500"/>
                  <measurement group_id="O2" value="497"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline phosphatase Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline phosphatase Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline phosphatase Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline phosphatase Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="451"/>
                  <measurement group_id="O2" value="453"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline phosphatase Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline phosphatase Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline phosphatase Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="510"/>
                  <measurement group_id="O2" value="518"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="457"/>
                  <measurement group_id="O2" value="471"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="516"/>
                  <measurement group_id="O2" value="520"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="464"/>
                  <measurement group_id="O2" value="472"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Urea Nitrogen Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="450"/>
                  <measurement group_id="O2" value="466"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Urea Nitrogen Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Urea Nitrogen Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Urea Nitrogen Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Urea Nitrogen Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="417"/>
                  <measurement group_id="O2" value="434"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Urea Nitrogen Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Urea Nitrogen Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Urea Nitrogen Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Calcium Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="516"/>
                  <measurement group_id="O2" value="519"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Calcium Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Calcium Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Calcium Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Calcium Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="461"/>
                  <measurement group_id="O2" value="468"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Calcium Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Calcium Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Calcium Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="407"/>
                  <measurement group_id="O2" value="402"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70"/>
                  <measurement group_id="O2" value="85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="355"/>
                  <measurement group_id="O2" value="367"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76"/>
                  <measurement group_id="O2" value="71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chlorine Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="518"/>
                  <measurement group_id="O2" value="518"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chlorine Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chlorine Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chlorine Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chlorine Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="466"/>
                  <measurement group_id="O2" value="472"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chlorine Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chlorine Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chlorine Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine phosphokinase Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="456"/>
                  <measurement group_id="O2" value="454"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine phosphokinase Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine phosphokinase Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine phosphokinase Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine phosphokinase Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="412"/>
                  <measurement group_id="O2" value="420"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine phosphokinase Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine phosphokinase Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine phosphokinase Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="510"/>
                  <measurement group_id="O2" value="509"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="453"/>
                  <measurement group_id="O2" value="466"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Direct bilirubin Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="500"/>
                  <measurement group_id="O2" value="494"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Direct bilirubin Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Direct bilirubin Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Direct bilirubin Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Direct bilirubin Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="457"/>
                  <measurement group_id="O2" value="458"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Direct bilirubin Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Direct bilirubin Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Direct bilirubin Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GGT Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="510"/>
                  <measurement group_id="O2" value="515"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GGT Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GGT Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GGT Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GGT Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="459"/>
                  <measurement group_id="O2" value="471"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GGT Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GGT Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GGT Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="468"/>
                  <measurement group_id="O2" value="464"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="409"/>
                  <measurement group_id="O2" value="423"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="509"/>
                  <measurement group_id="O2" value="509"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="462"/>
                  <measurement group_id="O2" value="470"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Leucine Amino Peptidase Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="510"/>
                  <measurement group_id="O2" value="512"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Leucine Amino Peptidase Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Leucine Amino Peptidase Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Leucine Amino Peptidase Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Leucine Amino Peptidase Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="460"/>
                  <measurement group_id="O2" value="462"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Leucine Amino Peptidase Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Leucine Amino Peptidase Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Leucine Amino Peptidase Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="486"/>
                  <measurement group_id="O2" value="491"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="433"/>
                  <measurement group_id="O2" value="437"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDH Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="519"/>
                  <measurement group_id="O2" value="521"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="466"/>
                  <measurement group_id="O2" value="474"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total bilirubin Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="472"/>
                  <measurement group_id="O2" value="466"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total bilirubin Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total bilirubin Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total bilirubin Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total bilirubin Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="440"/>
                  <measurement group_id="O2" value="443"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total bilirubin Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total bilirubin Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total bilirubin Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="318"/>
                  <measurement group_id="O2" value="324"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="177"/>
                  <measurement group_id="O2" value="176"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="275"/>
                  <measurement group_id="O2" value="290"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="164"/>
                  <measurement group_id="O2" value="158"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total protein Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="510"/>
                  <measurement group_id="O2" value="509"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total protein Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total protein Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total protein Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total protein Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="454"/>
                  <measurement group_id="O2" value="463"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total protein Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total protein Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total protein Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Uric acid Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="515"/>
                  <measurement group_id="O2" value="520"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Uric acid Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Uric acid Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Uric acid Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Uric acid Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="465"/>
                  <measurement group_id="O2" value="473"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Uric acid Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Uric acid Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Uric acid Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>pH Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="466"/>
                  <measurement group_id="O2" value="462"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>pH Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>pH Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>pH Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>pH Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="438"/>
                  <measurement group_id="O2" value="442"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>pH Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>pH Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>pH Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Normal [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Above [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Below [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Unknown [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="401"/>
                  <measurement group_id="O2" value="440"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Normal [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="126"/>
                  <measurement group_id="O2" value="96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Above [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Below [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CRP Unknown [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="373"/>
                  <measurement group_id="O2" value="409"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Abnormal Biochemical Parameters in Urine Samples</title>
        <description>Abnormalities in concentrations (expressed as milligrams per deciliter [mg/dL]) are presented categorical as follows:
Protein: &lt;10 (-)*; 10-25 (+-)*; 25-85 (+); 85-250 (2+); 250-800 (3+).
Glucose: &lt;30 (-)*; 30-60 (+-)*; 60-125 (+); 125-250 (2+); 250-750 (3+).
Urobilinogen: &lt;1.5 (+-)*; 1.5-3.5 (+); 3.5-7 (2+); 7-14 (3+).
Bilirubin: &lt;0.35 (-)*; 0.35-1.5 (+); 1.5-5 (2+); 5-12 (3+).
Occult blood: &lt;0.015 (-)*; 0.015-0.045 (+-); 0.045-015 (+); 0.15-0.75 (2+); &gt;0.75 (3+).
Ketone body: &lt;2.5 (-)*; 2.5-7.5 (+-); 7.5-30 (+); 30-70 (2+); 70-125 (3+).
Normal ranges indicated by asterix*.</description>
        <time_frame>At Month 0 and Month 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aimmugen Group</title>
            <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="519"/>
                  <measurement group_id="O2" value="521"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Abnormal Biochemical Parameters in Urine Samples</title>
            <description>Abnormalities in concentrations (expressed as milligrams per deciliter [mg/dL]) are presented categorical as follows:
Protein: &lt;10 (-)*; 10-25 (+-)*; 25-85 (+); 85-250 (2+); 250-800 (3+).
Glucose: &lt;30 (-)*; 30-60 (+-)*; 60-125 (+); 125-250 (2+); 250-750 (3+).
Urobilinogen: &lt;1.5 (+-)*; 1.5-3.5 (+); 3.5-7 (2+); 7-14 (3+).
Bilirubin: &lt;0.35 (-)*; 0.35-1.5 (+); 1.5-5 (2+); 5-12 (3+).
Occult blood: &lt;0.015 (-)*; 0.015-0.045 (+-); 0.045-015 (+); 0.15-0.75 (2+); &gt;0.75 (3+).
Ketone body: &lt;2.5 (-)*; 2.5-7.5 (+-); 7.5-30 (+); 30-70 (2+); 70-125 (3+).
Normal ranges indicated by asterix*.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Protein (-) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="496"/>
                  <measurement group_id="O2" value="492"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein (+-) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein (+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein (2+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein (3+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein (Unknown) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein (-) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="444"/>
                  <measurement group_id="O2" value="448"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein (+-) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein (+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein (2+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein (3+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein (Unknown) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose (-) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="513"/>
                  <measurement group_id="O2" value="520"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose (+-) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose (+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose (2+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose (3+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose (Unknown) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose (-) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="459"/>
                  <measurement group_id="O2" value="471"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose (+-) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose (+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose (2+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose (3+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose (Unknown) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen (-) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen (+-) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="506"/>
                  <measurement group_id="O2" value="502"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen (+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen (2+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen (3+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen (Unknown) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen (-) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen (+-) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="460"/>
                  <measurement group_id="O2" value="460"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen (+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen (2+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen (3+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen (Unknown) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Occult Blood (-) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="483"/>
                  <measurement group_id="O2" value="495"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Occult Blood (+-) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Occult Blood (+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Occult Blood (2+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Occult Blood (3+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Occult Blood (Unknown) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Occult Blood (-) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="393"/>
                  <measurement group_id="O2" value="398"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Occult Blood (+-) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Occult Blood (+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Occult Blood (2+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Occult Blood (3+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Occult Blood (Unknown) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ketone Body (-) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="501"/>
                  <measurement group_id="O2" value="506"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ketone Body (+-) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ketone Body (+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ketone Body (2+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ketone Body (3+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ketone Body (Unknown) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ketone Body (-) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="452"/>
                  <measurement group_id="O2" value="460"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ketone Body (+-) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ketone Body (+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ketone Body (2+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ketone Body (3+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ketone Body (Unknown) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin (-) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="517"/>
                  <measurement group_id="O2" value="520"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin (+-) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin (+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin (2+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin (3+) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin (Unknown) [Month 0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin (-) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="466"/>
                  <measurement group_id="O2" value="474"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin (+-) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin (+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin (2+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin (3+) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin (Unknown) [Month 7]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>- For serious adverse events: thoughout the study period (up to Month 24). - For other adverse events: -- during the 30-day (non-systematically assessed) or -- during the 7-day (systematically assessed) follow-up period after any vaccination.</time_frame>
      <desc>Total number of subjects at risk corresponds to
all subjects in the Total Vaccinated Cohort for serious events and non-systematically assessed other events;
those subjects in the Total Vaccinated Cohort with at least one documented dose.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.</description>
        </group>
        <group group_id="E2">
          <title>Aimmugen Group</title>
          <description>Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Mastitis postpartum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Eyeball rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Moyamoya disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Borderline personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Polycystic ovaries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic granulomatous angiitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="512" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="300" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="508" subjects_at_risk="512"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="455" subjects_at_risk="512"/>
                <counts group_id="E2" subjects_affected="287" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="401" subjects_at_risk="512"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="512"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="341" subjects_at_risk="512"/>
                <counts group_id="E2" subjects_affected="300" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="512"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="512"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="250" subjects_at_risk="512"/>
                <counts group_id="E2" subjects_affected="222" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="262" subjects_at_risk="512"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="512"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="521"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="521"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
